If AZ has to wait for the results of that second trial it will allow Dupixent to consolidate its position, and perhaps more significantly for Fasenra's prospects in CRSwNP allow Nucala to build ...

Patients may opt to take the others because of their less cumbersome dosing regime - Dupixent is administered every other week, while AZ’s Fasenra is given every eight weeks, and the others are ...

Dupixent’s approval in COPD comes after GSK’s anti-IL-5 antibody Nucala (mepolizumab) failed to pass muster with the ...